Effects of subcutaneous oestradiol implants on ovarian activity

Magos, A.; Collins, W. P.; Studd, J. W. W.

doi:10.1016/0020-7292(88)90147-6

Cited by 2 publications

(2 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…14 Oestradiol in perimenopausal women improves mood 2,22,23 and removes climacteric symptoms. In younger women in the appropriate dose, 24 it suppresses ovulation and the cyclical hormonal changes which produce the cyclical symptoms of PMS. Testosterone is useful because of its effect upon energy, libido as well as mood.…”

Section: Discussionmentioning

confidence: 99%

Hormone therapy for reproductive depression in women

Studd¹

2014

Post Reprod Health

View full text Add to dashboard Cite

An email survey of patients attending a PMS and Menopause Centre produced 238 patients whose principal presenting symptom was depression. Seventy-seven percent claimed to have had severe or moderate depression, 17% had had at least one psychotic episode and 14% had attempted suicide. Fifty-eight percent had seen a psychiatrist. Seventy-one percent had received antidepressants and 17% had received mood stabilising drugs. Twelve percent had been admitted to a psychiatric hospital and 3.8% had received electroconvulsive therapy. Sixty-eight percent had premenstrual syndrome as a teenager and 145 women (89%) out of 165 women who had been pregnant had no depression during pregnancy but 110 (66%) developed postnatal depression. Ninety-seven women (58%) who had been pregnant had suffered both premenstrual depression and postnatal depression. All were treated with transdermal estrogens and 93% also had transdermal testosterone. One hundred and seventy-one patients had a uterus and received cyclical progestogen to protect the endometrium and 63% of these developed the premenstrual syndrome-type symptoms of progesterone intolerance during the progestogen days. Thirty-five percent of patients claimed to be cured and 55% had a considerable improvement with estrogen therapy. Only 3.7% reported that there was no improvement. For 94%, the hormone therapy was a life-changing event for the better. None were worse. Forty patients had hysterectomy and bilateral oophorectomy for progesterone intolerance or heavy uterine bleeding and 38 replied that it was life changing for the better with less or no depression. It is concluded that premenstrual and postnatal depressions appear in the same vulnerable women. These women are typically well during pregnancy and are a sub group of reproductive depression which also develops climacteric depression in the transition phase. These types of depression are the product of hormonal changes and respond well to transdermal hormone therapy.

show abstract

Section: Discussionmentioning

confidence: 99%

Hormone therapy for reproductive depression in women

Studd¹

2014

Post Reprod Health

View full text Add to dashboard Cite

show abstract

“…A progressive dose-dependent suppression of LH and FSH was observed while the addition of a progestin dramatically increased the magnitude of gonadotrophin inhibition (Goldzieher et al, 1975). Later, s.c. E 2 implants (Magos et al, 1987) and E 2 transdermal patches (Watson et al, 1988) were also shown to be able to suppress ovulation. The exact mode of action by which estrogens induce suppression of ovulation remains to be elucidated.…”

Section: Estrogensmentioning

confidence: 95%

Residual ovarian activity during oral steroid contraception

Heusden¹

2002

Human Reproduction Update

View full text Add to dashboard Cite

Steroid drugs with contraceptive properties have been available in the clinical setting for over four decades and are still subject to improvement. Estrogens, progestins and anti-progestins have been used alone or in various combinations, regimens and routes of administration to favour the balance between efficacy and undesirable effects. One of the most important changes in this respect is the gradual lowering of steroid dosage in commercially available contraceptives. Current steroid contraceptive pills still achieve the goal of suppression of pituitary-ovarian activity, but the margins for error are minimal. In this review the available data on modes of action and the effects on suppressing pituitary-ovarian activity by different forms of oral contraception are reassessed. Although pregnancy rates provide a crude measure of contraceptive efficacy, no benchmark for pituitary-ovarian inhibition is available to test the suppressive potential of contraceptive drugs. Consequently, many studies provide incomplete and/or incomparable results. For the further study of those forms of steroid contraception that rely predominantly on suppression of ovarian activity, prevention of dominant follicles selection should be the objective.

show abstract

Effects of subcutaneous oestradiol implants on ovarian activity

Cited by 2 publications

References 11 publications

Hormone therapy for reproductive depression in women

Hormone therapy for reproductive depression in women

Residual ovarian activity during oral steroid contraception

Contact Info

Product

Resources

About